Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm	Recruiting	Phase 1 / Phase 2	2026-01-22		NCT02961101

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Han weidong	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Biotherapeutic Department of Chinese PLA General Hospital	Beijing	China	8

Clinical trials